BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1033 related articles for article (PubMed ID: 37141907)

  • 21. Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case-control study.
    Tartof SY; Slezak JM; Puzniak L; Hong V; Xie F; Ackerson BK; Valluri SR; Jodar L; McLaughlin JM
    Lancet Respir Med; 2022 Jul; 10(7):689-699. PubMed ID: 35468336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of vaccine booster, vaccine type, and hybrid immunity on humoral and cellular immunity against SARS-CoV-2 ancestral strain and Omicron variant sublineages BA.2 and BA.5 among older adults with comorbidities: a cross sectional study.
    Fong CH; Zhang X; Chen LL; Poon RW; Chan BP; Zhao Y; Wong CK; Chan KH; Yuen KY; Hung IF; Yuen JKY; To KK
    EBioMedicine; 2023 Feb; 88():104446. PubMed ID: 36706582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Herpes zoster related hospitalization after inactivated (CoronaVac) and mRNA (BNT162b2) SARS-CoV-2 vaccination: A self-controlled case series and nested case-control study.
    Wan EYF; Chui CSL; Wang Y; Ng VWS; Yan VKC; Lai FTT; Li X; Wong CKH; Chan EWY; Wong CSM; Leung KSM; Ni MY; Valkenburg SA; Peiris JSM; Wu JTK; Cowling BJ; Ashcroft DM; Hung IFN; Leung GM; Wong ICK
    Lancet Reg Health West Pac; 2022 Apr; 21():100393. PubMed ID: 35128500
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of BNT162b2 and CoronaVac vaccinations against mortality and severe complications after SARS-CoV-2 Omicron BA.2 infection: a case-control study.
    Yan VKC; Wan EYF; Ye X; Mok AHY; Lai FTT; Chui CSL; Li X; Wong CKH; Li PH; Ma T; Qin S; Wong VKC; Tsang TC; Tsui SH; Chui WCM; Cowling BJ; Leung GM; Lau CS; Wong ICK; Chan EWY
    Emerg Microbes Infect; 2022 Dec; 11(1):2304-2314. PubMed ID: 35980089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. COVID-19 lateral flow IgG seropositivity and serum neutralising antibody responses after primary and booster vaccinations in Chile: a cross-sectional study.
    Sauré D; O'Ryan M; Torres JP; Zuñiga M; Soto-Rifo R; Valiente-Echeverría F; Gaete-Argel A; Neira I; Saavedra V; Acevedo ML; Archila C; Acuña F; Rain M; Basso LJ
    Lancet Microbe; 2023 Mar; 4(3):e149-e158. PubMed ID: 36716754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study.
    Barin B; Kasap U; Selçuk F; Volkan E; Uluçkan Ö
    Lancet Microbe; 2022 Apr; 3(4):e274-e283. PubMed ID: 35165669
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
    Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
    Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study.
    Yung CF; Pang D; Kam KQ; Lye DC; Ong B; Chong CY; Tan KB
    Lancet Child Adolesc Health; 2023 Jul; 7(7):463-470. PubMed ID: 37201540
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults.
    Niyomnaitham S; Quan Toh Z; Wongprompitak P; Jansarikit L; Srisutthisamphan K; Sapsutthipas S; Jantraphakorn Y; Mingngamsup N; Licciardi PV; Chokephaibulkit K
    Hum Vaccin Immunother; 2022 Nov; 18(6):2091865. PubMed ID: 35816053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. COVID-19 Mortality and Vaccine Coverage - Hong Kong Special Administrative Region, China, January 6, 2022-March 21, 2022.
    Smith DJ; Hakim AJ; Leung GM; Xu W; Schluter WW; Novak RT; Marston B; Hersh BS
    MMWR Morb Mortal Wkly Rep; 2022 Apr; 71(15):545-548. PubMed ID: 35421076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of mRNA and inactivated COVID-19 vaccines: A test-negative study in an infection-naïve Hong Kong population.
    Ng RWY; Sze RKH; Chong KC; Zhao S; Ling L; Lui G; Leung ASY; Yeung ACM; Ho WCS; Wong MCS; Chen Z; Boon SS; Hui DSC; Chan PKS
    J Infect; 2023 Aug; 87(2):136-143. PubMed ID: 37245544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance.
    Fleming-Dutra KE; Britton A; Shang N; Derado G; Link-Gelles R; Accorsi EK; Smith ZR; Miller J; Verani JR; Schrag SJ
    JAMA; 2022 Jun; 327(22):2210-2219. PubMed ID: 35560036
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of the booster dose of inactivated COVID-19 vaccine against Omicron BA.5 infection: a matched cohort study of adult close contacts.
    Zeng T; Lu Y; Zhao Y; Guo Z; Sun S; Teng Z; Tian M; Wang J; Li S; Fan X; Wang W; Cai Y; Liao G; Liang X; He D; Wang K; Zhao S
    Respir Res; 2023 Oct; 24(1):246. PubMed ID: 37828565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS-CoV-2 vaccine (CoronaVac) on risks of all-cause mortality, emergency department visit, and unscheduled hospitalization.
    Wong CKH; Xiong X; Lau KTK; Chui CSL; Lai FTT; Li X; Chan EWY; Wan EYF; Au ICH; Cowling BJ; Lee CK; Wong ICK
    BMC Med; 2022 Mar; 20(1):119. PubMed ID: 35296305
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age.
    Khan FL; Nguyen JL; Singh TG; Puzniak LA; Wiemken TL; Schrecker JP; Taitel MS; Zamparo JM; Jodar L; McLaughlin JM
    JAMA Netw Open; 2022 Dec; 5(12):e2246915. PubMed ID: 36515946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of COVID-19 Vaccination on Healthcare Worker Infection Rate and Outcome during SARS-CoV-2 Omicron Variant Outbreak in Hong Kong.
    Zee ST; Kwok LF; Kee KM; Fung LH; Luk WP; Chan TL; Leung CP; Yu PW; Hung J; SzeTo KY; Chan WL; Tang SF; Lin WC; Ma SK; Lee KH; Lau CC; Yung WH
    Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016210
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022.
    Cheng SM; Mok CKP; Chan KC; Ng SS; Lam BH; Luk LL; Ko FW; Chen C; Yiu K; Li JK; Chan KK; Tsang LC; Poon LL; Hui DS; Peiris M
    Euro Surveill; 2022 May; 27(18):. PubMed ID: 35514306
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of primary series and booster vaccination against SARS-CoV-2 infection and hospitalisation among adolescents aged 12-17 years in Singapore: a national cohort study.
    Chiew CJ; Premikha M; Chong CY; Wei WE; Ong B; Lye DC; Heng D; Lee VJ; Tan KB
    Lancet Infect Dis; 2023 Feb; 23(2):177-182. PubMed ID: 36182678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: a randomised, observer-masked, controlled trial in Indonesia.
    Fadlyana E; Setiabudi D; Kartasasmita CB; Putri ND; Rezeki Hadinegoro S; Mulholland K;
    Lancet Infect Dis; 2023 May; 23(5):545-555. PubMed ID: 36640798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
    Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
    Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 52.